Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 7 results
Author
[
Title
]
Type
Year
Filters:
Author
is
Colombel, Jean-Frederic
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
V
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
S
Faleck DM
,
Winters A
,
Chablaney S
,
Shashi P
,
Meserve J
,
Weiss A
,
Aniwan S
,
Koliani-Pace JL
,
Kochhar G
,
Boland BS
et al.
. 2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
P
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
E
Sandborn WJ
,
Feagan BG
,
Loftus EV
,
Peyrin-Biroulet L
,
Van Assche G
,
D'Haens G
,
Schreiber S
,
Colombel J-F
,
Lewis JD
,
Ghosh S
et al.
. 2020.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
.
Gastroenterology. 158(8):2123-2138.e8.
D
Agrawal M
,
Cohen-Mekelburg S
,
Kayal M
,
Axelrad J
,
Galati J
,
Tricomi B
,
Kamal K
,
Faye AS
,
Abrudescu P
,
Scherl E
et al.
. 2019.
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.
.
Aliment Pharmacol Ther. 49(5):564-571.
Dulai PS
,
Singh S
,
Casteele NVande
,
Meserve J
,
Winters A
,
Chablaney S
,
Aniwan S
,
Shashi P
,
Kochhar G
,
Weiss A
et al.
. 2020.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.